摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3,5-dicyclopropyl-1-(2-fluoro-4-nitrophenyl)-1H-pyrazole | 1288339-32-1

中文名称
——
中文别名
——
英文名称
3,5-dicyclopropyl-1-(2-fluoro-4-nitrophenyl)-1H-pyrazole
英文别名
3,5-dicyclopropyl-1-(2-fluoro-4-nitrophenyl)pyrazole
3,5-dicyclopropyl-1-(2-fluoro-4-nitrophenyl)-1H-pyrazole化学式
CAS
1288339-32-1
化学式
C15H14FN3O2
mdl
——
分子量
287.293
InChiKey
MFVNFBDWFSFCJW-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3
  • 重原子数:
    21
  • 可旋转键数:
    3
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.4
  • 拓扑面积:
    63.6
  • 氢给体数:
    0
  • 氢受体数:
    4

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL
    申请人:Muthuppalaniappan Meyyappan
    公开号:US20110105447A1
    公开(公告)日:2011-05-05
    Disclosed are novel calcium release-activated calcium (CRAC) channel inhibitors, methods for preparing them, pharmaceutical compositions containing them, and methods of treatment using them. The present disclosure also relates to methods for treating non-small cell lung cancer (NSCLC) with CRAC inhibitors, and to methods for identifying therapeutics for treating and of diagnosing cancer.
    本发明涉及一种新的释放激活(CRAC)通道抑制剂,以及制备它们的方法,包含它们的制药组合物和使用它们的治疗方法。本发明还涉及使用CRAC抑制剂治疗非小细胞肺癌(NSCLC)的方法,以及识别治疗和诊断癌症的治疗剂的方法。
  • NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL AND METHODS FOR TREATMENT OF NON-SMALL CELL LUNG CANCER
    申请人:MUTHUPPALANIAPPAN MEYYAPPAN
    公开号:US20110112058A1
    公开(公告)日:2011-05-12
    Disclosed are novel calcium release-activated calcium (CRAC) channel inhibitors, methods for preparing them, pharmaceutical compositions containing them, and methods of treatment using them. The present disclosure also relates to methods for treating non-small cell lung cancer (NSCLC) with CRAC inhibitors, and to methods for identifying therapeutics for treating and of diagnosing cancer.
    本发明涉及一种新型的释放激活(CRAC)通道抑制剂,其制备方法,包含它们的药物组合物以及使用它们的治疗方法。本发明还涉及使用CRAC抑制剂治疗非小细胞肺癌(NSCLC)的方法,以及识别用于治疗和诊断癌症的治疗剂的方法。
  • Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer
    申请人:Muthuppalaniappan Meyyappan
    公开号:US08993612B2
    公开(公告)日:2015-03-31
    Disclosed are novel calcium release-activated calcium (CRAC) channel inhibitors, methods for preparing them, pharmaceutical compositions containing them, and methods of treatment using them. The present disclosure also relates to methods for treating non-small cell lung cancer (NSCLC) with CRAC inhibitors, and to methods for identifying therapeutics for treating and of diagnosing cancer.
    本发明涉及新型的释放激活的(CRAC)通道抑制剂,制备它们的方法,包含它们的药物组合物,以及使用它们的治疗方法。本公开还涉及使用CRAC抑制剂治疗非小细胞肺癌(NSCLC)的方法,以及用于诊断和治疗癌症的治疗剂的识别方法。
  • Modulators of calcium release-activated calcium channel
    申请人:Rhizen Pharmaceuticals SA
    公开号:US08921364B2
    公开(公告)日:2014-12-30
    Disclosed are novel calcium release-activated calcium (CRAC) channel inhibitors, methods for preparing them, pharmaceutical compositions containing them, and methods of treatment using them. The present disclosure also relates to methods for treating non-small cell lung cancer (NSCLC) with CRAC inhibitors, and to methods for identifying therapeutics for treating and of diagnosing cancer.
    本发明涉及一种新型的释放激活(CRAC)通道抑制剂,其制备方法,含有它们的制药组合物以及使用它们的治疗方法。本公开还涉及使用CRAC抑制剂治疗非小细胞肺癌(NSCLC)的方法,以及用于诊断和治疗癌症的治疗药物的识别方法。
  • PYRAZOLE DERIVATIVES AS MODULATORS OF CALCIUM RELEASE -ACTIVATED CALCIUM CHANNEL
    申请人:Rhizen Pharmaceuticals S.A.
    公开号:EP2509955A1
    公开(公告)日:2012-10-17
查看更多